- Home
- PAYS vs REPL Comparison
PAYS vs REPL Comparison
Compare PAYS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYS | REPL |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.7M | 407.1M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PAYS | REPL |
|---|---|---|
| Price | $8.29 | $11.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $9.42 | $5.67 |
| AVG Volume (30 Days) | 591.7K | ★ 3.8M |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.71 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $24,120,434.00 | N/A |
| Revenue This Year | $33.83 | N/A |
| Revenue Next Year | $14.89 | N/A |
| P/E Ratio | $95.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $1.50 |
| 52 Week High | $8.88 | $13.24 |
Technical Indicators
Market Signals| Indicator | PAYS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 70.22 |
| Support Level | $5.01 | $6.81 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.42 | 0.92 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 82.93 | 73.98 |
Price Performance
Historical ComparisonAbout PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.